James Rubenstein, MD, PhD

Title(s)Professor, Medicine
SchoolSchool of Medicine
Address513 Parnassus Ave, HSE, #1260
San Francisco CA 94143
Phone415-502-4430
PronounsDOM IT Supported
ORCID ORCID Icon0000-0002-9062-2449 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    University of California, San FranciscoResidency School of Medicine

    Collapse Overview 
    Collapse overview
    Dr. James Rubenstein is a hematologist-oncologist, or a specialist in blood disorders. He has particular expertise in treating patients with neurologic complications from cancer, including patients with non-Hodgkin's lymphoma involving the brain (called central nervous system lymphoma). He also specializes in patients with cancer that has spread to the brain from other parts of the body.

    In his research, Rubenstein investigates immunologic tools to improve tumor response to chemotherapy and radiation treatment, and to minimize toxicity from treatment. He is also interested in developing tumor biomarkers to diagnose brain tumors.

    Rubenstein earned his medical degree at Weill Cornell Medicine and completed a residency in internal medicine at Stanford Medicine. He earned a doctorate in molecular and cellular neurosciences at the Rockefeller University. He completed a fellowship in hematology and oncology at UCSF, which included training in neuro-oncology.

    Rubenstein has won research awards from the Leukemia & Lymphoma Society and the National Cancer Institute. He is a member of the American Society of Hematology, American Society of Clinical Oncology and American Association for Cancer Research.

    Collapse Research 
    Collapse research activities and funding
    Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NF-kB Activation and Response in Primary CNS Lymphoma
    NIH R01CA239462Jul 4, 2019 - Jun 30, 2024
    Role: Principal Investigator
    Targeted Therapies in CNS Lymphomas
    NIH R21CA184694Apr 14, 2014 - Mar 31, 2016
    Role: Principal Investigator
    Recognition and Targeting of CNS Lymphoma by Tumor-Associated Macrophages
    NIH R01CA139083Apr 1, 2009 - Jul 31, 2020
    Role: Principal Investigator
    Molecular Classification and therapy of CNS Lymphomas
    NIH K23CA100291Aug 4, 2004 - Jul 31, 2009
    Role: Principal Investigator
    General Clinical Research Center
    NIH M01RR000079Dec 1, 1974 - Mar 31, 2009
    Role: Co-Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Collaboration Interests

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Identification of genomic biomarkers of disease progression and survival in primary CNS lymphoma. Blood Adv. 2025 Mar 11; 9(5):1117-1131. Geng H, Mo S, Chen L, Ballapuram A, Tsang M, Lu M, Rauschecker AM, Wen KW, Devine WP, Solomon DA, Rubenstein JL. PMID: 39536287; PMCID: PMC11914178.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Small molecule protein assembly modulators with pan-cancer therapeutic efficacy. Open Biol. 2024 Dec; 14(12):240210. Lingappa AF, Akintunde O, Samueli E, Ewald C, Michon M, Ziari N, Lu M, Yu SF, Froehlich M, Le PU, Fernandez Y, Mallesh S, Lin J, Kitaygorodskyy A, Solas D, Reed JC, Lingappa JR, Müller-Schiffmann A, Korth C, Prasad D, Nalca A, Aston E, Fabbri B, Anand SK, Campi TW, Petrouski E, Dey D, Andrews DW, Rubenstein JL, Lingappa VR. PMID: 39689856; PMCID: PMC11651915.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    3. Clinicopathologic features of primary central nervous system anaplastic large cell lymphoma: a multicenter study identifies age and ALK status as prognostic factors. J Hematop. 2024 Dec; 17(4):215-222. Morrow WP, Milligan NS, Ohgami RS, Young KH, Wang B, Vega F, Marques-Piubelli ML, Feldman AL, Slack GW, Savage KJ, Zhao X, Rubenstein JL, Hsi ED. PMID: 39549220.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Toll-like Receptor 7/8 Pathway Is a Therapeutic Target in Primary CNS Lymphoma. Blood. 2024 Nov 5; 144(Supplement 1):978-978. Randall RM, Geng GH, Chen CL, Ballapuram BA, Yung YC, Lu LM, Chin CG, Mish MM, Bates BJ, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    5. Trial in Progress - Alliance A051901 - Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed By Lenalidomide and Nivolumab Maintenance in Primary Central Nervous System Lymphoma (PCNSL). Blood. 2024 Nov 5; 144(Supplement 1):4502.4. Alencar AA, Bobek BO, Mehta-Shah MN, Epperla EN, Lu-Emerson LC, Rutherford RS, Olszewski OA, Ollila OT, Singer SS, Dockter DT, Geyer GS, Rosenstein RL, De La Fuente DM, Hsi HE, Dinner DS, Rubenstein RJ, Bartlett BN, Leonard LJ. .
      View in: Publisher Site   Mentions:
    6. BTK Degradation As a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Patient-Derived, Rodent Models. Blood. 2024 Nov 5; 144(Supplement 1):2988-2988. Ma MJ, Randall RM, Lu LM, Chen CL, Geng GH, Kumar KA, Malla MS, Noviski NM, Rountree RR, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    7. Myeloablative vs nonmyeloablative consolidation for primary central nervous system lymphoma: results of Alliance 51101. Blood Adv. 2024 06 25; 8(12):3189-3199. Batchelor TT, Giri S, Ruppert AS, Geyer SM, Smith SE, Mohile N, Swinnen LJ, Friedberg JW, Kahl BS, Bartlett NL, Hsi ED, Cheson BD, Wagner-Johnston N, Nayak L, Leonard JP, Rubenstein JL. PMID: 38598710; PMCID: PMC11225669.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    8. Utility of PD-1, PD-L1, and IDO-1 Stains in Ocular Extranodal Marginal Zone Lymphoma (MZL) and Diffuse Large B-cell Lymphoma (DLBCL). Appl Immunohistochem Mol Morphol. 2024 Sep 01; 32(8):395-399. Craig A, Güney E, Pekmezci M, Bloomer M, Laszik Z, Ohgami RS, Toland A, Vogel H, Forns T, Wang E, Rubenstein J, Wen KW. PMID: 38899518.
      View in: PubMed   Mentions:    Fields:    
    9. Liquid biopsy for improving diagnosis and monitoring of CNS lymphomas: A RANO review. Neuro Oncol. 2024 06 03; 26(6):993-1011. Nayak L, Bettegowda C, Scherer F, Galldiks N, Ahluwalia M, Baraniskin A, von Baumgarten L, Bromberg JEC, Ferreri AJM, Grommes C, Hoang-Xuan K, Kühn J, Rubenstein JL, Rudà R, Weller M, Chang SM, van den Bent MJ, Wen PY, Soffietti R. PMID: 38598668; PMCID: PMC11145457.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    10. Trial in Progress: A Phase I/II Study of Tafasitamab Plus Lenalidomide in Patients with Relapsed CNS Lymphoma. Blood. 2023 Nov 28; 142(Supplement 1):3104. Randall RM, Rauschecker RA, Gima-Lange GL, Wilmoth WJ, Chen CL, Lu LM, Geng GH, Abdulhaq AH, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    11. Molecular profiling identifies at least 3 distinct types of posttransplant lymphoproliferative disorder involving the CNS. Blood Adv. 2023 07 11; 7(13):3307-3311. Guney E, Lucas CG, Singh K, Pekmezci M, Fernandez-Pol S, Mirchia K, Toland A, Vogel H, Bannykh S, Schafernak KT, Alexandrescu S, Mobley BC, Powell S, Davidson CJ, Neltner J, Boué DR, Hattab E, Ferris SP, Ohgami RS, Rubenstein JL, Bollen AW, Tihan T, Perry A, Solomon DA, Wen KW. PMID: 36897259; PMCID: PMC10336256.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    12. IDENTIFICATION OF GENOMIC BIOMARKERS OF DISEASE PROGRESSION AND SURVIVAL IN NEWLY-DIAGNOSED PRIMARY CNS LYMPHOMA. Hematological Oncology. 2023 Jun 9; 41(S2):40-41. Mo MS, Geng GH, Ballapuram BA, Chen CL, Lu LM, Devine DW, Wen WK, Solomon SD, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    13. BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Proof of Concept Studies in Intracranial Preclinical including Patient-Derived Models. Hematological Oncology. 2023 Jun 9; 41(S2):546-547. Ma MJ, Lu LM, Chen CL, Geng GH, Kumar KA, Noviski NM, Rountree RR, Guiducci GC, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    14. Older patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers. Am J Hematol. 2023 06; 98(6):900-912. David KA, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Bond DA, Agrawal P, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Folstad M, Kumar P, Ollila TA, Cai J, Spurgeon S, Sieg A, Cleveland J, Chang J, Epperla N, Karmali R, Naik S, Martin P, Smith SM, Rubenstein J, Kahl B, Evens AM. PMID: 36965007; PMCID: PMC10979647.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    15. EBV-positive PCNSL in older patients: incidence, characteristics, tumor pathology, and outcomes across a large multicenter cohort. Leuk Lymphoma. 2023 05; 64(5):1026-1034. Agrawal P, David KA, Chen Z, Sundaram S, Kim SH, Vaca R, Lin Y, Singer S, Malecek MK, Carter J, Zayac A, Kim MS, Reddy N, Ney D, Habib A, Strouse C, Graber J, Bachanova V, Salman S, Vendiola JA, Hossain N, Tsang M, Major A, Gandhi MK, Keane C, Bond DA, Folstad M, Chang J, Mier-Hicks A, Torka P, Rajakumar P, Venugopal P, Berg S, Glantz M, Goldlust SA, Matnani R, Kumar P, Ollila TA, Cai J, Spurgeon SE, Sieg AG, Cleveland J, Epperla N, Karmali R, Naik S, Smith SM, Rubenstein JL, Kahl BS, Chadburn A, Evens AM, Martin P. PMID: 36960939.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    16. Stereotactic Radiosurgery for Primary Central Nervous System Lymphoma. Cureus. 2023 Feb; 15(2):e34817. Wu SY, Braunstein SE, Rubenstein JL, Sneed PK. PMID: 36915845; PMCID: PMC10008121.
      View in: PubMed   Mentions: 2  
    17. Tafasitamab at the blood-brain barrier. Br J Haematol. 2023 04; 201(1):154-157. Rauschecker AM, Mo SS, Randall M, Shen-Sampas J, Rubenstein JL. PMID: 36691708.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    18. Next-Generation Sequencing of Newly-Diagnosed Primary CNS Lymphoma Reveals Alterations in BTG1, ETV6, and 6p Are Associated with Chemoresistance and Inferior Progression-Free Survival. Blood. 2022 Nov 15; 140(Supplement 1):3516-3517. Mo MS, Geng GH, Cerejo CM, Wen WK, Solomon SD, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    19. Primary CNS lymphoma: update on molecular pathogenesis and therapy. Leuk Lymphoma. 2023 01; 64(1):57-65. Mo SS, Cleveland J, Rubenstein JL. PMID: 36286546.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    20. Primary CNS Lymphoma: Progress With Dose-Intensive Consolidation. J Clin Oncol. 2022 11 10; 40(32):3681-3687. Rubenstein JL. PMID: 36179277; PMCID: PMC9649280.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    21. Acquired factor VII inhibitor associated with primary central nervous system Lymphoma: A case report. EJHaem. 2022 Aug; 3(3):1000-1002. Goyal V, Salmasi G, Leavitt AD, Rubenstein JL, Banerjee R. PMID: 36051043; PMCID: PMC9421997.
      View in: PubMed   Mentions: 2  
    22. A genetically distinct pediatric subtype of primary CNS large B-cell lymphoma is associated with favorable clinical outcome. Blood Adv. 2022 05 24; 6(10):3189-3193. Güney E, Lucas CG, Qi Z, Yu J, Zhang R, Ohgami RS, Rubenstein JL, Boué DR, Schafernak K, Wertheim GB, Dahiya S, Giulino-Roth L, Attarbaschi A, Barth MJ, Kothari S, Abla O, Cohen AL, Mendez JS, Bollen A, Perry A, Tihan T, Pekmezci M, Solomon DA, Wen KW. PMID: 35157770; PMCID: PMC9131901.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    23. Regulation of CNS Lymphoma Progression By the Myeloid Microenvironment. Blood. 2021 Nov 5; 138(Supplement 1):448-448. Gao GH, Fraser FE, Merlini MM, Geng GH, Chen CL, Lu LM, Moshfegh MY, Cleveland CJ, Ryu RJ, Sharma SJ, Solomon SD, Akassoglou AK, Lowell LC, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    24. Tumor metabolism and neurocognition in CNS lymphoma. Neuro Oncol. 2021 10 01; 23(10):1668-1679. Geng H, Tsang M, Subbaraj L, Cleveland J, Chen L, Lu M, Sharma J, Vigneron DB, Kurhanewicz J, LaFontaine M, Luks T, Barshop BA, Gangoiti J, Villanueva-Meyer JE, Rubenstein JL. PMID: 33625503; PMCID: PMC8485453.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    25. Primary central nervous system lymphoma in older adults and the rationale for maintenance strategies: a narrative review. Ann Lymphoma. 2021 Sep; 5. Tsang M, Rubenstein JL, Pulczynski EJ. PMID: 35106521; PMCID: PMC8802984.
      View in: PubMed   Mentions: 1  
    26. A functional mammalian display screen identifies rare antibodies that stimulate NK cell-mediated cytotoxicity. Proc Natl Acad Sci U S A. 2021 08 03; 118(31). Kang E, Kadoch C, Rubenstein JL, Lanier LL, Wells JA. PMID: 34330834; PMCID: PMC8346823.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    27. Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro Oncol. 2021 07 01; 23(7):1056-1071. Barajas RF, Politi LS, Anzalone N, Schöder H, Fox CP, Boxerman JL, Kaufmann TJ, Quarles CC, Ellingson BM, Auer D, Andronesi OC, Ferreri AJM, Mrugala MM, Grommes C, Neuwelt EA, Ambady P, Rubenstein JL, Illerhaus G, Nagane M, Batchelor TT, Hu LS. PMID: 33560416; PMCID: PMC8248856.
      View in: PubMed   Mentions: 66     Fields:    Translation:Humans
    28. Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance). Journal of Clinical Oncology. 2021 May 20; 39(15_suppl):7506-7506. Batchelor BT, Giri GS, Ruppert RA, Bartlett BN, Hsi HE, Cheson CB, Nayak NL, Leonard LJ, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    29. Blood Coagulation Factor Fibrinogen in Tumor Pathogenesis of Central Nervous System B-Cell Lymphoma. Am J Pathol. 2021 03; 191(3):575-583. Chan JP, Merlini M, Gao HX, Mendiola AS, Akassoglou K, Rubenstein JL, Ryu JK. PMID: 33608067; PMCID: PMC7919853.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    30. Survival and Patient-Reported Outcomes of Older Adults with Primary Central Nervous System Lymphoma on Low-Dose Lenalidomide. Blood. 2020 Nov 5; 136(Supplement 1):21-22. Tsang TM, Cleveland CJ, Cerejo CM, Geng GH, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    31. On point in primary CNS lymphoma. Hematol Oncol. 2020 Dec; 38(5):640-647. Tsang M, Cleveland J, Rubenstein JL. PMID: 32510610; PMCID: PMC8815361.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimals
    32. Cutaneous T-Cell Lymphoma PDX Drug Screening Platform Identifies Cooperation between Inhibitions of PI3Kα/δ and HDAC. J Invest Dermatol. 2021 02; 141(2):364-373. Wu CH, Yang CY, Wang L, Gao HX, Rakhshandehroo T, Afghani S, Pincus L, Balassanian R, Rubenstein J, Gill R, Bandyopadhyay S, McCormick F, Moasser M, Ai WZ. PMID: 32603749; PMCID: PMC10286854.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansAnimalsCells
    33. Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of induction therapy in Alliance 51101. Journal of Clinical Oncology. 2020 May 20; 38(15_suppl):8042-8042. Batchelor BT, Giri GS, Ruppert RA, Bartlett BN, Hsi HE, Cheson CB, Nayak NL, Leonard LJ, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    34. THERAPEUTIC VITRECTOMY AS AN ADJUNCT TREATMENT TO SYSTEMIC CHEMOTHERAPY FOR INTRAOCULAR LYMPHOMA. Retin Cases Brief Rep. 2020; 14(2):116-119. Bever GJ, Kim DJ, Afshar AR, Rubenstein JL, Damato BE. PMID: 29210961; PMCID: PMC6089662.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    35. Development of a Pathway-Directed Drug Screen Platform for Cutaneous T Cell Lymphoma Using Patient-Derived Xenograft Models. Blood. 2019 Nov 13; 134(Supplement_1):1578-1578. WU WC, Yang YC, Wang WL, Gao GH, Taha TR, Afghani AS, Pincus PL, Balassanian BR, Rubenstein RJ, Gill GR, Bandyopadhyay BS, McCormick MF, Moasser MM, Ai AW. .
      View in: Publisher Site   Mentions:
    36. Potential Genetic and Immunologic Mechanisms of Therapeutic Resistance and Disease Progression in CNS Lymphoma Elucidated Via Whole Brain Autopsy Studies. Blood. 2019 Nov 13; 134(Supplement_1):1494-1494. Solomon SD, Geng GH, Sobel SR, Subbaraj SL, Tsang TM, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    37. Maintenance lenalidomide in primary CNS lymphoma. Ann Oncol. 2019 08 01; 30(8):1397-1398. Rubenstein JL, Geng H, Vu K, Mannis G, Formaker P, Hwang J, Munster PN, Damato B. PMID: 31046114; PMCID: PMC8887569.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    38. An audit of retinal lymphoma treatment at the University of California San Francisco. Eye (Lond). 2020 03; 34(3):515-522. Damato B, Bever GJ, Kim DJ, Afshar AR, Rubenstein JL. PMID: 31358925; PMCID: PMC7042248.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    39. Evolving Treatments for Primary Central Nervous System Lymphoma. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:454-466. Ferreri AJM, Holdhoff M, Nayak L, Rubenstein JL. PMID: 31099614.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    40. Comprehensive approach to diagnosis and treatment of newly diagnosed primary CNS lymphoma. Neuro Oncol. 2019 02 19; 21(3):296-305. Grommes C, Rubenstein JL, DeAngelis LM, Ferreri AJM, Batchelor TT. PMID: 30418592; PMCID: PMC6380418.
      View in: PubMed   Mentions: 92     Fields:    Translation:Humans
    41. Low-dose lenalidomide maintenance after induction therapy in older patients with primary central nervous system lymphoma. Br J Haematol. 2019 07; 186(1):180-183. Vu K, Mannis G, Hwang J, Geng H, Rubenstein JL. PMID: 30714128; PMCID: PMC8776513.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    42. Application of Hyperpolarized 13C Magnetic Resonance Imaging to Detect Target Inhibition of NFkB Activation in Preclinical Patient-Derived Models of CNS Lymphoma. Blood. 2018 Nov 29; 132(Supplement 1):2840-2840. Geng GH, Tiret TB, Gao GH, Kadoch KC, Lu LM, Chen CL, Park PI, Melkus MG, Elkhaled EA, Kurhanewicz KJ, Drew DL, Degorce DS, Mayo MM, Dillman DK, Anjum AR, Bloecher BA, Chaumeil CM, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    43. Low-Dose Lenalidomide Maintenance after Induction Therapy in Older Patients with Primary CNS Lymphoma. Blood. 2018 Nov 29; 132(Supplement 1):4230-4230. Vu VK, Rubenstein RJ, Mannis MG, Hwang HJ, Geng GH. .
      View in: Publisher Site   Mentions:
    44. RTHP-31. STEREOTACTIC RADIOSURGERY FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA. Neuro-Oncology. 2018 Nov 5; 20(suppl_6):vi231-vi231. Wu WS, Braunstein BS, Rubenstein RJ, Sneed SP. .
      View in: Publisher Site   Mentions:
    45. Can rituximab unlock the innate potential of checkpoint blockade in the CNS? Leuk Lymphoma. 2019 02; 60(2):281-283. Rubenstein JL. PMID: 30188237.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    46. Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma. Blood Adv. 2018 07 10; 2(13):1595-1607. Rubenstein JL, Geng H, Fraser EJ, Formaker P, Chen L, Sharma J, Killea P, Choi K, Ventura J, Kurhanewicz J, Lowell C, Hwang J, Treseler P, Sneed PK, Li J, Wang X, Chen N, Gangoiti J, Munster PN, Damato B. PMID: 29986852; PMCID: PMC6039666.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansCTClinical Trials
    47. Abstract 4975: Tumor metabolism and cognitive dysfunction in CNS lymphoma. Cancer Research. 2018 Jul 1; 78(13_Supplement):4975-4975. Subbaraj SL, Geng GH, Sharma SJ, LaFontaine LM, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    48. Insights from a Case of Vitreoretinal Lymphoma. Ocul Oncol Pathol. 2019 Jan; 5(1):13-19. Damato BE, Bever GJ, Afshar AR, Rubenstein JL. PMID: 30675472; PMCID: PMC6341330.
      View in: PubMed   Mentions: 5  
    49. Biology of CNS lymphoma and the potential of novel agents. Hematology Am Soc Hematol Educ Program. 2017 12 08; 2017(1):556-564. Rubenstein JL. PMID: 29222305; PMCID: PMC6053314.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    50. EXTH-71. HYPERPOLARIZED [1-13C] PYRUVATE AS A BIOMARKER FOR TREATMENT MONITORING IN LYMPHOMA MURINE MODELS. Neuro-Oncology. 2017 Nov 6; 19(suppl_6):vi88-vi88. Tiret TB, Autry AA, Park PI, Lu LM, Anjum AR, Drew DL, Degorce DS, Mayo MM, Dillman DK, Rubenstein RJ, Chaumeil CM. .
      View in: Publisher Site   Mentions:
    51. Preliminary analysis of lenalidomide maintenance after methotrexate-temozolomide-rituximab induction in older patients with PCNSL. Hematological Oncology. 2017 Jun 1; 35(S2):343-344. Rubenstein RJ, Hwang HJ, Mannis MG. .
      View in: Publisher Site   Mentions:
    52. CHECKMATE 647: A PHASE 2, OPEN-LABEL STUDY OF NIVOLUMAB IN RELAPSED/REFRACTORY PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA OR RELAPSED/REFRACTORY PRIMARY TESTICULAR LYMPHOMA. Hematological Oncology. 2017 Jun 1; 35(S2):420-421. Nayak NL, Iwamoto IF, Ferreri FA, Santoro SA, Singer SS, Batlevi BC, Batchelor BT, Rubenstein RJ, Johnston JP, Ramchandren RR, Soussain SC, Drappatz DJ, Becker BK, Witzens-Harig WM, Illerhaus IG, Herrera HA, Masood MA, Shipp SM. .
      View in: Publisher Site   Mentions:
    53. Regression of methotrexate-resistant AIDS-related primary central nervous system lymphoma with lenalidomide plus combination anti-retroviral therapy. Leuk Lymphoma. 2017 11; 58(11):2748-2751. Gupta NK, Wang CC, Mannis GN, Yu JJ, Rubenstein JL. PMID: 28395565; PMCID: PMC6026016.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    54. Targeting NF-KB Activation in Novel Intracranial Models of CNS Lymphoma. Blood. 2016 Dec 2; 128(22):777-777. Geng GH, Gao GH, Kadoch KC, Lu LM, Chen CL, Anjum AR, Drew DL, Degorce DS, Dillman DK, Mayo MM, Anderson AS, Collins CC, Lowell LC, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    55. The Challenge of Primary Central Nervous System Lymphoma. Hematol Oncol Clin North Am. 2016 Dec; 30(6):1293-1316. Carnevale J, Rubenstein JL. PMID: 27888882; PMCID: PMC5127405.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    56. ATIM-27. PHASE I INVESTIGATION OF LENALIDOMIDE PLUS RITUXIMAB AND OUTCOMES OF LENALIDOMIDE MAINTENANCE IN RECURRENT CNS LYMPHOMA. Neuro-Oncology. 2016 Nov 1; 18(suppl_6):vi23-vi24. Rubenstein RJ, Fraser FE, Formaker FP, Lee LJ, Chen CN, Kock KM, Cheung CW, Killea KP, Choi CK, Wang WX, Munster MP, Damato DB. .
      View in: Publisher Site   Mentions:
    57. Long-term survival in AIDS-related primary central nervous system lymphoma. Neuro Oncol. 2017 01; 19(1):99-108. Gupta NK, Nolan A, Omuro A, Reid EG, Wang CC, Mannis G, Jaglal M, Chavez JC, Rubinstein PG, Griffin A, Abrams DI, Hwang J, Kaplan LD, Luce JA, Volberding P, Treseler PA, Rubenstein JL. PMID: 27576871; PMCID: PMC5193026.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    58. Abstract A06: Development of a drug discovery platform using clinically relevant patient-derived xenograft models for cutaneous T cell lymphomas. Clinical Cancer Research. 2016 Aug 15; 22(16_Supplement):a06-a06. Ai AW, Yang YY, Afghani AS, Gao GH, Pincus PL, Wang WL, Rakhshandhroo RT, Balassanian BR, Rubenstein RJ, Gill GR, McCormick MF. .
      View in: Publisher Site   Mentions:
    59. Phase I investigation of lenalidomide plus rituximab and outcomes of lenalidomide maintenance in recurrent CNS lymphoma. Journal of Clinical Oncology. 2016 May 20; 34(15_suppl):7502-7502. Rubenstein RJ, Fraser FE, Formaker FP, Lee LJ, Chen CN, Kock KM, Cheung CW, Wang WX, Munster MP, Damato DB. .
      View in: Publisher Site   Mentions:
    60. The role of whole brain radiation in primary CNS lymphoma. Blood. 2016 07 07; 128(1):32-6. Kasenda B, Loeffler J, Illerhaus G, Ferreri AJ, Rubenstein J, Batchelor TT. PMID: 27207798; PMCID: PMC4968379.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    61. Therapy for Secondary CNS Involvement in Malignant Lymphomas: No Standard Yet! J Clin Oncol. 2016 05 20; 34(15):1829-30. Korfel A, Chamberlain M, Neuwelt E, Thiel E, Doolittle N, Schlegel U, Dreyling M, Rubenstein J, Fischer L, Björkholm M, Martus P, Weller M, Glantz M. PMID: 27001566; PMCID: PMC5321044.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    62. Expression of B and T Lymphocyte Attenuator (BTLA) Correlates with CNS Metastasis and Adverse Prognosis in Activated B-Cell Lymphoma and Acute Lymphoblastic Leukemia. Blood. 2015 Dec 3; 126(23):3900-3900. Geng GH, Chen CZ, Anderson AS, Fraser FE, Lu LM, Lingjing LC, Collins CC, Markus MM, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    63. Performance of Apparent Diffusion Coefficient Values and Conventional MRI Features in Differentiating Tumefactive Demyelinating Lesions From Primary Brain Neoplasms. AJR Am J Roentgenol. 2015 Nov; 205(5):1075-85. Mabray MC, Cohen BA, Villanueva-Meyer JE, Valles FE, Barajas RF, Rubenstein JL, Cha S. PMID: 26496556; PMCID: PMC4679155.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    64. Prolonged Complete Response in a Pediatric Patient With Primary Peripheral T-Cell Lymphoma of the Central Nervous System. Pediatr Hematol Oncol. 2015; 32(8):529-34. Shalabi H, Angiolillo A, Vezina G, Rubenstein JL, Pittaluga S, Raffeld M, Marcus L. PMID: 26384083; PMCID: PMC4942274.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    65. New approaches in primary central nervous system lymphoma. Chin Clin Oncol. 2015 Mar; 4(1):11. Fraser E, Gruenberg K, Rubenstein JL. PMID: 25841718; PMCID: PMC4942281.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    66. 77-year-old woman with a dural-based mass. Marginal zone B-cell lymphoma (MZBCL). Brain Pathol. 2015 Jan; 25(1):111-2. Okimoto RA, Perry A, Rubenstein JL. PMID: 25521182; PMCID: PMC4942276.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    67. Interim Results of a Phase I Study of Lenalidomide (CC-5013) Plus Intraventricular/Intravenous Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma. Blood. 2014 Dec 6; 124(21):4470-4470. Rubenstein RJ, Formaker FP, Wang WX, Chen CN, Seider SM, Munster MP, Damato DB. .
      View in: Publisher Site   Mentions:
    68. Progress in central nervous system lymphomas. Br J Haematol. 2014 Aug; 166(3):311-25. Wang CC, Carnevale J, Rubenstein JL. PMID: 24837460; PMCID: PMC4107064.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    69. Reply to M.C. Chamberlain. J Clin Oncol. 2014 Mar 10; 32(8):858-9. Rubenstein JL, Cheson BD, Jung SH, Kaplan LD. PMID: 24493718; PMCID: PMC3940542.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    70. 50 Brain Metastases and Neoplastic Meningitis. . 2014 Jan 1; (Cancer 94 10 2002):725-738.e4. Sneed SP, Kased KN, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    71. CNS Lymphoma. Rare Lymphomas. 2014 Jan 1; 207-223. Korfel KA, Rubenstein RJ, Ott OG, Hsi HE. .
      View in: Publisher Site   Mentions:
    72. Novel Intracranial Xenografts Of CNS Lymphoma Implicate a Role For Cereblon As a Mediator Of Lenalidomide Efficacy. Blood. 2013 Nov 15; 122(21):374-374. Gao GH, Anderson AS, Kadoch KC, Maiti MM, Chen CL, Yao YD, Melkus MG, Wang WM, Ren RY, Breider BM, Heise HC, Lowell LC, Collins CC, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    73. Obesity and Hepatitis B Infection and Risk Of Primary CNS Lymphoma. Blood. 2013 Nov 15; 122(21):4298-4298. Wang WC, Bracci BP, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    74. High-Dose Methotrexate Is Effective, Safe, and Leads To Durable Responses In Patients With AIDS-Related Primary Central Nervous System Lymphoma Treated During The Era Of Combined Anti-Retroviral Therapy. Blood. 2013 Nov 15; 122(21):1792-1792. Gupta GN, Hwang HJ, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    75. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. Clin Cancer Res. 2014 Feb 15; 20(4):1029-41. Kadoch C, Li J, Wong VS, Chen L, Cha S, Munster P, Lowell CA, Shuman MA, Rubenstein JL. PMID: 24190981; PMCID: PMC3944388.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    76. How I treat CNS lymphomas. Blood. 2013 Oct 03; 122(14):2318-30. Rubenstein JL, Gupta NK, Mannis GN, Lamarre AK, Treseler P. PMID: 23963042; PMCID: PMC3790503.
      View in: PubMed   Mentions: 75     Fields:    Translation:Humans
    77. The roles of tumor associated macrophages and interferon gamma in immune surveillance in CNS lymphoma (P2211). The Journal of Immunology. 2013 May 1; 190(1_Supplement):170.62-170.62. Gao GH, Wong WV, Chen CL, Locksley LR, Lowell LC, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    78. CXCL13 plus interleukin 10 is highly specific for the diagnosis of CNS lymphoma. Blood. 2013 Jun 06; 121(23):4740-8. Rubenstein JL, Wong VS, Kadoch C, Gao HX, Barajas R, Chen L, Josephson SA, Scott B, Douglas V, Maiti M, Kaplan LD, Treseler PA, Cha S, Hwang JH, Cinque P, Cyster JG, Lowell C. PMID: 23570798; PMCID: PMC3674672.
      View in: PubMed   Mentions: 109     Fields:    Translation:HumansAnimalsCells
    79. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013 Sep 01; 31(25):3061-8. Rubenstein JL, Hsi ED, Johnson JL, Jung SH, Nakashima MO, Grant B, Cheson BD, Kaplan LD. PMID: 23569323; PMCID: PMC3753699.
      View in: PubMed   Mentions: 191     Fields:    Translation:HumansCTClinical Trials
    80. A systematic approach to the diagnosis of suspected central nervous system lymphoma. JAMA Neurol. 2013 Mar 01; 70(3):311-9. Scott BJ, Douglas VC, Tihan T, Rubenstein JL, Josephson SA. PMID: 23319132; PMCID: PMC4135394.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansAnimals
    81. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood. 2013 Jan 31; 121(5):745-51. Rubenstein JL, Li J, Chen L, Advani R, Drappatz J, Gerstner E, Batchelor T, Krouwer H, Hwang J, Auerback G, Kadoch C, Lowell C, Munster P, Cha S, Shuman MA, Damon LE. PMID: 23197589; PMCID: PMC3563362.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansCTClinical Trials
    82. BCL6 Expression and Treatment Delay Correlate with Adverse Outcome in Newly Diagnosed Primary CNS Lymphoma: Final Report of CALGB 50202 (Alliance). Blood. 2012 Nov 16; 120(21):301-301. Rubenstein RJ, Hsi HE, Johnson JJ, Jung JS, Grant GB, Cheson CB, Kaplan KL. .
      View in: Publisher Site   Mentions:
    83. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI. Clin Cancer Res. 2012 Feb 15; 18(4):1146-55. Wieduwilt MJ, Valles F, Issa S, Behler CM, Hwang J, McDermott M, Treseler P, O'Brien J, Shuman MA, Cha S, Damon LE, Rubenstein JL. PMID: 22228634; PMCID: PMC3288204.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansCTClinical Trials
    84. Biology of Primary Central Nervous System Lymphoma. Lymphoma and Leukemia of the Nervous System. 2012 Jan 1; 99-111. Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    85. Multicenter Phase I Trial of Intraventricular Immuno-Chemotherapy in Recurrent CNS Lymphoma. Blood. 2011 Nov 18; 118(21):959-959. Rubenstein RJ, Chen CL, Advani AR, Drappatz DJ, Gerstner GE, Batchelor BT, Krouwer KH, Kadoch KC, Munster MP, Cha CS, Shuman SM, Damon DL. .
      View in: Publisher Site   Mentions:
    86. Combined Diffusion and Perfusion MRI As Biomarkers of Prognosis in Immunocompetent Patients with Primary CNS Lymphoma. Blood. 2011 Nov 18; 118(21):2655-2655. Valles VF, Regalado RS, Rubenstein RJ, Cha CS. .
      View in: Publisher Site   Mentions:
    87. Dynamic Changes in Macrophage Polarization Correlate with Progression and Response in CNS Lymphoma: Insights Into the Transcriptome of Lymphoma-Associated M2 Macrophages,. Blood. 2011 Nov 18; 118(21):3219-3219. Kadoch KC, Wong WV, Chen CL, Bet-Lachin BA, Roy RR, Hyun HW, Behler BC, Lowell LC, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    88. Genomic and Molecular Properties of Relapsed CNS Lymphoma Using Novel Primary Meningeal Lymphoma Cell Lines and Intracranial Xenografts,. Blood. 2011 Nov 18; 118(21):3477-3477. Gao GH, Anderson AS, Chen CL, Kadoch KC, Hann HB, Lowell LC, Collins CC, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    89. Metabolic Profiling of CNS Lymphoma and Its Microenvironment. Blood. 2011 Nov 18; 118(21):588-588. Bet-Lachin BA, Jiang JF, Chen CL, Keshari KK, Wilson WD, Kurhanewicz KJ, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    90. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium. Oncologist. 2011; 16(11):1589-99. Chan CC, Rubenstein JL, Coupland SE, Davis JL, Harbour JW, Johnston PB, Cassoux N, Touitou V, Smith JR, Batchelor TT, Pulido JS. PMID: 22045784; PMCID: PMC3233294.
      View in: PubMed   Mentions: 159     Fields:    Translation:HumansAnimals
    91. Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy. J Clin Oncol. 2011 Jul 10; 29(20):e595-7. Rubenstein JL, Treseler PA, Stewart PJ. PMID: 21519022; PMCID: PMC3675664.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    92. Intensive Chemotherapy and Immunotherapy, without Brain Irradiation, In Newly Diagnosed Patients with Primary CNS Lymphoma: Results of CALGB 50202. Blood. 2010 Nov 19; 116(21):763-763. Rubenstein RJ, Johnson JJ, Jung JS, Cheson CB, Kaplan KL. .
      View in: Publisher Site   Mentions:
    93. Interim results of a phase I trial of intraventricular rituximab plus methotrexate in recurrent CNS lymphoma: Macrophage polarization and acquired resistance to therapy. Journal of Clinical Oncology. 2010 May 20; 28(15_suppl):2532-2532. Rubenstein RJ, Kadoch KC, Wong WV, Hyun HW, Lowell LC. .
      View in: Publisher Site   Mentions:
    94. Abstract 5580: Macrophage polarization and acquired resistance to rituximab in CNS lymphoma. Clinical Research. 2010 Apr 15; 5580-5580. Kadoch KC, Wong WV, Rambaldo RT, Hyun HW, Gao GH, Lowell LC, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    95. Abstract 2728: Multivariate analysis of cerebrospinal fluid protein biomarkers in central nervous system lymphoma patients and controls. Clinical Research. 2010 Apr 15; 2728-2728. Wong WV, Chen CL, Kadoch KC, Tsang TA, Siu SL, Lowell LC, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    96. Macrophage Polarization and Acquired Resistance to Rituximab in CNS Lymphoma. Blood. 2009 Nov 20; 114(22):3749-3749. Kadoch KC, Wong WV, Rambaldo RT, Hyun HW, Lowell LC, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    97. Biology and treatment of primary central nervous system lymphoma. Neurotherapeutics. 2009 Jul; 6(3):587-97. Algazi AP, Kadoch C, Rubenstein JL. PMID: 19560747; PMCID: PMC4942275.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    98. Reply to H. Zetterberg et al. Journal of Clinical Oncology. 2009 May 1; 27(13):2303-2304. Rubenstein RJ, Chen CL, Kadoch KC, Roy RS, Becker BC, Schulman SH. .
      View in: Publisher Site   Mentions:
    99. Pathologic correlates of primary central nervous system lymphoma defined in an orthotopic xenograft model. Clin Cancer Res. 2009 Mar 15; 15(6):1989-97. Kadoch C, Dinca EB, Voicu R, Chen L, Nguyen D, Parikh S, Karrim J, Shuman MA, Lowell CA, Treseler PA, James CD, Rubenstein JL. PMID: 19276270; PMCID: PMC4372389.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    100. Insights into the biology of primary central nervous system lymphoma. Curr Oncol Rep. 2009 Jan; 11(1):73-80. Mrugala MM, Rubenstein JL, Ponzoni M, Batchelor TT. PMID: 19080745; PMCID: PMC4110181.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    101. Differential gene expression in central nervous system lymphoma. Blood. 2009 Jan 01; 113(1):266-7; author reply 267-8. Rubenstein JL, Shen A, Batchelor TT, Kadoch C, Treseler P, Shuman MA. PMID: 19122120; PMCID: PMC2614638.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    102. Sarcoidosis of the pineal gland: an unusual presentation of neurosarcoidosis. J Neurooncol. 2009 Jan; 91(1):113-6. Yang I, Delpolyi A, Sughrue ME, Rubenstein J, Bollen AW, Parsa AT. PMID: 18759061; PMCID: PMC4134350.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    103. Primary lymphoma of the central nervous system: epidemiology, pathology and current approaches to diagnosis, prognosis and treatment. Leuk Lymphoma. 2008; 49 Suppl 1:43-51. Rubenstein J, Ferreri AJ, Pittaluga S. PMID: 18821432; PMCID: PMC4110179.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    104. Chapter 56 Brain Metastases and Neoplastic Meningitis. Abeloff\u0027s Clinical Oncology. 2008 Jan 1; 827-844. Sneed SP, Kased KN, Huang HK, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    105. Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol. 2008 Jan 01; 26(1):96-105. Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL. PMID: 18056677; PMCID: PMC4134101.
      View in: PubMed   Mentions: 69     Fields:    Translation:Humans
    106. Complement Activation and Resistance within the Cerebrospinal Fluid Following Intraventricular Administration of Anti-CD20 in the Treatment of Recurrent CNS Lymphoma. Blood. 2007 Nov 16; 110(11):3418-3418. Kadoch KC, Shuman SM, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    107. Treatment of Primary CNS Lymphoma with Induction High-Dose Methotrexate, Temozolomide, Rituximab Followed by Consolidation Cytarabine/Etoposide: A Pilot Study with Biomarker Analysis. Blood. 2007 Nov 16; 110(11):1364-1364. Issa IS, Shen SA, Karch KJ, Kadoch KC, Shuman SM, Damon DL, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    108. In Reply. Journal of Clinical Oncology. 2007 Oct 1; 25(28):4509-4511. Rubenstein RJ, Abrey AL, Advani AR, Shuman SM, Tsai TT, O'Brien OJ. .
      View in: Publisher Site   Mentions:
    109. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol. 2007 Apr 10; 25(11):1350-6. Rubenstein JL, Fridlyand J, Abrey L, Shen A, Karch J, Wang E, Issa S, Damon L, Prados M, McDermott M, O'Brien J, Haqq C, Shuman M. PMID: 17312328.
      View in: PubMed   Mentions: 113     Fields:    Translation:HumansCTClinical Trials
    110. Molecular pathogenesis of primary central nervous system lymphoma. Neurosurg Focus. 2006 Nov 15; 21(5):E1. Kadoch C, Treseler P, Rubenstein JL. PMID: 17134111.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    111. Identification of CSF Biomarkers for the Diagnosis of CNS Lymphoma. Blood. 2006 Nov 1; 108(11):2036-2036. Rubenstein RJ, Kadoch KC, Karch KJ, Josephson JA, Issa IS, Becker BC, Schulman SH, Damon DL, Shuman SM, Roy RS. .
      View in: Publisher Site   Mentions:
    112. Treatment of primary CNS lymphoma with induction high-dose methotrexate, temozolomide, rituximab followed by consolidation cytarabine/etoposide: A pilot study with biomarker analysis. Journal of Clinical Oncology. 2006 Jun 20; 24(18_suppl):7595-7595. Issa IS, Hwang HJ, Karch KJ, Fridlyand FJ, Prados PM, Batchelor BT, Aldape AK, Haqq HC, Damon DL, Rubenstein RJ. .
      View in: Publisher Site   Mentions:
    113. Gene expression and angiotropism in primary CNS lymphoma. Blood. 2006 May 01; 107(9):3716-23. Rubenstein JL, Fridlyand J, Shen A, Aldape K, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, Shuman M. PMID: 16418334; PMCID: PMC1895776.
      View in: PubMed   Mentions: 79     Fields:    Translation:Humans
    114. Surgically (laparotomy/laparoscopy) guided placement of high dose rate interstitial irradiation catheters (LG-HDRT): technique and outcome. Gynecol Oncol. 2006 Jan; 100(1):145-8. Orr JW, Dosoretz DD, Mahoney D, Roland PY, Kelly FJ, Blitzer P, Nakfoor B, Katin M, Rubenstein J, Boothby RR. PMID: 16249021.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    115. Pathology and genetics of primary central nervous system and intraocular lymphoma. Hematol Oncol Clin North Am. 2005 Aug; 19(4):705-17, vii. Rubenstein JL, Treseler P, O'Brien JM. PMID: 16083831.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    116. Primary CNS lymphoma of T-cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol. 2005 Apr 01; 23(10):2233-9. Shenkier TN, Blay JY, O'Neill BP, Poortmans P, Thiel E, Jahnke K, Abrey LE, Neuwelt E, Tsang R, Batchelor T, Harris N, Ferreri AJ, Ponzoni M, O'Brien P, Rubenstein J, Connors JM. PMID: 15800313.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    117. Primary Central Nervous System Lymphoma of T Cell Origin: A Descriptive Analysis of 45 Cases from the International PCNSL Collaborative Group. Blood. 2004 Nov 16; 104(11):1372-1372. Shenkier ST, Blay BJ, O’Neill OB, Poortmans PP, Janke JK, Abrey AL, Neuwelt NE, Tsang TR, Batchelor BT, Harris HN, Ferreri FA, Ponzoni PM, O’Brien OP, Rubenstein RJ, Connors CJ. .
      View in: Publisher Site   Mentions:
    118. Results from a phase I study of intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis. Journal of Clinical Oncology. 2004 Jul 15; 22(14_suppl):6593-6593. Rubenstein RJ, Shen SA, Abrey AL, Combs CD, Haqq HC, Damon DL, O'Brien OJ, O'Connor OP, Prados PM, Shuman SM. .
      View in: Publisher Site   Mentions:
    119. Results from a phase I study of intraventricular administration of rituximab in patients with recurrent lymphomatous meningitis. Journal of Clinical Oncology. 2004 Jul 15; 22(14_suppl):6593-6593. Rubenstein RJ, Shen SA, Abrey AL, Combs CD, Haqq HC, Damon DL, O'Brien OJ, O'Connor OP, Prados PM, Shuman SM. .
      View in: Publisher Site   Mentions:
    120. Brain Metastases from Genitourinary Cancer: Germ Cell, Testicular, Prostate and Bladder Cancer. Intracranial Metastases. 2004 Jan 1; 352-361. Theodosopoulos TP, Rubenstein RJ, McDermott MM. .
      View in: Publisher Site   Mentions:
    121. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003 Jan 15; 101(2):466-8. Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, Aldape K, Shen A, Lee D, Grillo-Lopez A, Shuman MA. PMID: 12393404.
      View in: PubMed   Mentions: 152     Fields:    Translation:Animals
    122. Hemorrhage and VEGF expression in a case of primary CNS lymphoma. J Neurooncol. 2002 May; 58(1):53-6. Rubenstein J, Fischbein N, Aldape K, Burton E, Shuman M. PMID: 12160141.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    123. Sorting of striatal and cortical interneurons regulated by semaphorin-neuropilin interactions. Science. 2001 Aug 03; 293(5531):872-5. Marín O, Yaron A, Bagri A, Tessier-Lavigne M, Rubenstein JL, Rubenstein JL. PMID: 11486090.
      View in: PubMed   Mentions: 136     Fields:    Translation:AnimalsCells
    124. Tbr1 regulates differentiation of the preplate and layer 6. Neuron. 2001 Feb; 29(2):353-66. Hevner RF, Shi L, Justice N, Hsueh Y, Sheng M, Smiga S, Bulfone A, Goffinet AM, Campagnoni AT, Rubenstein JL, Rubenstein JL. PMID: 11239428.
      View in: PubMed   Mentions: 375     Fields:    
    125. Cell migration from the ganglionic eminences is required for the development of hippocampal GABAergic interneurons. Neuron. 2000 Dec; 28(3):727-40. Pleasure SJ, Anderson S, Hevner R, Bagri A, Marin O, Lowenstein DH, Rubenstein JL, Rubenstein JL. PMID: 11163262.
      View in: PubMed   Mentions: 125     Fields:    Translation:AnimalsCells
    126. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia. 2000 Jul-Aug; 2(4):306-14. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA. PMID: 11005565; PMCID: PMC1550290.
      View in: PubMed   Mentions: 201     Fields:    Translation:HumansAnimalsCells
    127. Hippocampus development and generation of dentate gyrus granule cells is regulated by LEF1. Development. 2000 Feb; 127(3):469-82. Galceran J, Miyashita-Lin EM, Devaney E, Rubenstein JL, Rubenstein JL, Grosschedl R. PMID: 10631168.
      View in: PubMed   Mentions: 121     Fields:    Translation:AnimalsCells
    128. Mice lacking the homeodomain transcription factor Nkx2.2 have diabetes due to arrested differentiation of pancreatic beta cells. Development. 1998 Jun; 125(12):2213-21. Sussel L, Kalamaras J, Hartigan-O'Connor DJ, Meneses JJ, Pedersen RA, Rubenstein JL, Rubenstein JL, German MS. PMID: 9584121.
      View in: PubMed   Mentions: 199     Fields:    Translation:Animals
    James's Networks
    Concepts (338)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (71)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-13-gbc789823 on PROFILES-PWEB03.

    Copyright © The Regents of the University of California.